Cargando…
Targeting BRD9 for Cancer Treatment: A New Strategy
Bromodomain-containing protein 9 (BRD9) is a newly identified subunit of the non-canonical barrier-to-autointegration factor (ncBAF) complex and a member of the bromodomain family IV. Studies have confirmed that BRD9 plays an oncogenic role in multiple cancer types, by regulating tumor cell growth....
Autores principales: | Zhu, Xiuzuo, Liao, Yi, Tang, Liling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769155/ https://www.ncbi.nlm.nih.gov/pubmed/33380808 http://dx.doi.org/10.2147/OTT.S286867 |
Ejemplares similares
-
Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells
por: Zhou, Lixin, et al.
Publicado: (2021) -
Exploring the Value of BRD9 as a Biomarker, Therapeutic Target and Co-Target in Prostate Cancer
por: Barma, Nafisa, et al.
Publicado: (2021) -
BRD4 as a Therapeutic Target in Pulmonary Diseases
por: Guo, Xia, et al.
Publicado: (2023) -
BRD4: An emerging prospective therapeutic target in glioma
por: Yang, Hua, et al.
Publicado: (2021) -
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
por: Brien, Gerard L, et al.
Publicado: (2018)